Company / Cash & Equivalents
SAB Biotherapeutics, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$10.5M
FY2025
5-year range
$8.9M / $56.6M
FY2021-FY2025
Trend
+18.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $57M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2025 with a 3-year CAGR of -31.9%.
Declined from $57M to $11M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -31.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -31.9%, indicating a declining trend.
- In FY2025, cash & equivalents increased 18.0% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.5M | +18.0% |
| FY2024 | $8.9M | -84.3% |
| FY2023 | $56.6M | +70.3% |
| FY2022 | $33.2M | +163.3% |
| FY2021 | $12.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026